Paper · 22473773
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
Shan J and 17 others. Hepatology, 2012. Cited by 263 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Papers, record 22473773. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22473773
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Homeodomain Proteins | Major topic |
| Liver Neoplasms | Major topic |
| Neoplastic Stem Cells | Major topic |
| Receptor, IGF Type 1 | Major topic |
| Humans | |
| Nanog Homeobox Protein | |
| Signal Transduction |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by167
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 263 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,934,724 | The evolving role of TP53 mutation in hepatocellular carcinoma (HCC). | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42934724 | PubMed |
| 41,781,591 | A different perspective on the cancer stem cell theory. | Med Oncol | 2026 | https://conductscience.org/library/papers/41781591 | PubMed |
| 41,376,750 | Role of OCT-4 and NANOG in the Malignant Transformation of Oral Submucous Fibrosis: An Immunohistochemical Evaluation. | Cureus | 2025 | https://conductscience.org/library/papers/41376750 | PubMed |
| 41,094,524 | ANXA2 in hepatocellular carcinoma: orchestrating tumorigenesis, progression, and therapeutic resistance toward precision targeting. | J Transl Med | 2025 | https://conductscience.org/library/papers/41094524 | PubMed |
| 41,058,987 | Negative associations between macronutrient quality index and lung cancer incidence and mortality: results from the prostate, lung, colorectal, and ovarian cancer screening trial. | Front Nutr | 2025 | https://conductscience.org/library/papers/41058987 | PubMed |
| 40,858,857 | High-content confocal analysis of tumorigenesis, cancer stem cells, and drug response in 3D cholangiocarcinoma cultures. | Sci Rep | 2025 | https://conductscience.org/library/papers/40858857 | PubMed |
| 40,847,555 | Persistent lineage plasticity driving lung cancer development and progression. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40847555 | PubMed |
| 40,844,657 | Signaling pathways as the pivotal regulators of cisplatin resistance in tumor cells through SOX2 upregulation. | Med Oncol | 2025 | https://conductscience.org/library/papers/40844657 | PubMed |
| 40,676,293 | PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40676293 | PubMed |
| 40,647,402 | Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647402 | PubMed |
1 to 10 of 167
See all 167 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IGF1R | 3,480 | PubTator's text mining | https://conductscience.org/library/genes/3480 | NCBI Gene |
| IGF2 | 3,481 | PubTator's text mining | https://conductscience.org/library/genes/3481 | NCBI Gene |
| NANOG | 79,923 | PubTator's text mining | https://conductscience.org/library/genes/79923 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22473773
GET https://conductscience.org/api/papers/v1/22473773/cited_by?page=2